Follicular Lymphoma | Tumor

Phase 2 Interim Analysis Shows Improved Response in Patients with Follicular Lymphoma

August 12th 2020, 4:00am

Article

“These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments,” said Dr. John Tsai.

'No Question' Patients with Follicular Lymphoma Can Benefit from FDA's Approval of Tazverik

July 13th 2020, 7:00pm

Article

“Having new options is important, particularly when patients have already been through chemotherapy and some of the other therapies that are available,” said Dr. John P. Leonard.

FDA Approves Tazverik for Certain Patients With Relapsed/Refractory Follicular Lymphoma

June 18th 2020, 10:26pm

Article

The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.